ATE396734T1 - Mittel für intravitreale verabreichung zur behandlung oder vorbeugung von augenerkrankungen - Google Patents

Mittel für intravitreale verabreichung zur behandlung oder vorbeugung von augenerkrankungen

Info

Publication number
ATE396734T1
ATE396734T1 AT00916034T AT00916034T ATE396734T1 AT E396734 T1 ATE396734 T1 AT E396734T1 AT 00916034 T AT00916034 T AT 00916034T AT 00916034 T AT00916034 T AT 00916034T AT E396734 T1 ATE396734 T1 AT E396734T1
Authority
AT
Austria
Prior art keywords
urea
eye
derivatives
prevention
agents
Prior art date
Application number
AT00916034T
Other languages
English (en)
Inventor
David Castillejos
Original Assignee
Vitreo Retinal Technologies In
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitreo Retinal Technologies In filed Critical Vitreo Retinal Technologies In
Application granted granted Critical
Publication of ATE396734T1 publication Critical patent/ATE396734T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AT00916034T 1999-03-02 2000-03-02 Mittel für intravitreale verabreichung zur behandlung oder vorbeugung von augenerkrankungen ATE396734T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12250399P 1999-03-02 1999-03-02

Publications (1)

Publication Number Publication Date
ATE396734T1 true ATE396734T1 (de) 2008-06-15

Family

ID=22403079

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916034T ATE396734T1 (de) 1999-03-02 2000-03-02 Mittel für intravitreale verabreichung zur behandlung oder vorbeugung von augenerkrankungen

Country Status (16)

Country Link
EP (1) EP1165095B1 (de)
JP (2) JP2002538125A (de)
KR (1) KR20010108296A (de)
CN (2) CN1377272A (de)
AT (1) ATE396734T1 (de)
AU (2) AU780299B2 (de)
BG (1) BG105867A (de)
BR (1) BR0008674A (de)
CA (1) CA2366050C (de)
DE (1) DE60039043D1 (de)
ES (1) ES2307498T3 (de)
IL (2) IL145226A0 (de)
MX (1) MXPA01008729A (de)
NZ (1) NZ513836A (de)
RU (1) RU2286157C2 (de)
WO (1) WO2000051620A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199574A1 (en) 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
US7977385B2 (en) 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
EP1443931B1 (de) * 2001-07-20 2007-03-28 Iomed, Inc. Iontophoretische okularvorrichtung zur abgabe von medikamenten auf methotrexat-basis und deren verwendung zur behandlung von neoplastischen, angiogenen, fibroplastischen und/oder immunsuppressiven augenunregelmässigkeiten
AU2002316724A1 (en) * 2001-07-20 2003-03-03 Iomed, Inc. Ophthalmic use of 5 fluorourcil
MXPA04007802A (es) * 2002-02-13 2005-04-19 Vitreo Retinal Technologies In Tratamiento de desordenes oftalmicos utilizando urea o derivados de urea.
BR0308403A (pt) * 2002-03-14 2005-01-18 Vitreo Retinal Technologies In Método para tratamento de um distúrbio do olho de um paciente humano ou veterinário, e, uso de um composto
MXJL02000046A (es) * 2002-12-13 2004-06-24 Jimenez Bayardo Arturo Solucion inyectable intravitrea para el tratamiento de hemorragias vitreas.
CN101385697B (zh) * 2008-10-30 2012-10-03 中国科学院上海药物研究所 氟比洛芬酯眼用纳米乳-原位凝胶制剂及其制备方法
RU2497498C2 (ru) * 2012-02-14 2013-11-10 Константин Николаевич Руссков Фармацевтическая композиция для профилактики пролиферативной клеточной реакции "митомицин-о"
AU2013201465B2 (en) * 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
CN103393631B (zh) * 2013-08-22 2015-04-08 北京蓝丹医药科技有限公司 一种氟比洛芬酯药物组合物
US20170020909A1 (en) * 2014-03-11 2017-01-26 Massachusetts Eye And Ear Infirmary Methods of treating glaucoma using amp-activated protein kinase (ampk) activators
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
PL3331517T3 (pl) * 2015-08-06 2020-06-29 Centre Hospitalier National D'ophtalmologie Quinze-Vingts Zastosowanie hydroksymocznika w celu zapobiegania brakowi perfuzji w siatkówce
US20190031762A1 (en) 2016-03-10 2019-01-31 Thrombogenics Nv Posterior ocular fibrosis inhibition by antagonizing placental growth factor
IL264842B (en) * 2016-08-18 2022-08-01 Troy Bremer Delivery of urea to macular and retinal cells using liposome constructs
WO2018208826A1 (en) * 2017-05-08 2018-11-15 Meharry Medical College Hydroxyurea to enhance sperm cells
GB2573784B (en) * 2018-05-17 2020-10-07 Nova Bio Pharma Product Dev Ltd A stable aqueous hydroxycarbamide solution
CN108721327A (zh) * 2018-08-24 2018-11-02 苏州药明康德新药开发股份有限公司 实验动物视网膜色素变性试验模型的制备方法
EP3920986A4 (de) * 2019-02-08 2022-10-26 Ohio State Innovation Foundation Antioxidantienfreisetzende glaskörperersatzstoffe und deren verwendungen
JP2022146830A (ja) * 2021-03-22 2022-10-05 均 石井 網膜剥離治療薬。

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0244178A3 (de) * 1986-04-28 1989-02-08 Iolab, Inc Intraokuläre Mittel und Verfahren zu deren Verwendung
ZA886757B (en) * 1987-09-11 1990-05-30 Syntex Inc Preservative system for ophthalmics formulations
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
US5441984A (en) * 1994-01-06 1995-08-15 Eli Lilly And Company Urea, thiourea and guanidine derivatives
CA2201134A1 (en) * 1994-10-10 1996-04-18 Alfred Sallmann Ophthalmic and aural compositions containing diclofenac potassium
US5891084A (en) * 1994-12-27 1999-04-06 Lee; Vincent W. Multiple chamber catheter delivery system
US5554187A (en) * 1995-08-18 1996-09-10 Rizzo, Iii; Joseph Medication dispensing intra-ocular lens system

Also Published As

Publication number Publication date
EP1165095A4 (de) 2004-12-15
JP5428101B2 (ja) 2014-02-26
CN101711737A (zh) 2010-05-26
AU2005202579A1 (en) 2005-07-07
MXPA01008729A (es) 2003-06-24
ES2307498T3 (es) 2008-12-01
AU3720100A (en) 2000-09-21
BR0008674A (pt) 2002-02-13
CN1377272A (zh) 2002-10-30
EP1165095A1 (de) 2002-01-02
IL145226A0 (en) 2002-06-30
CA2366050C (en) 2011-05-24
NZ513836A (en) 2004-01-30
KR20010108296A (ko) 2001-12-07
WO2000051620A1 (en) 2000-09-08
JP2011088911A (ja) 2011-05-06
BG105867A (en) 2002-04-30
AU780299B2 (en) 2005-03-17
JP2002538125A (ja) 2002-11-12
EP1165095B1 (de) 2008-05-28
RU2286157C2 (ru) 2006-10-27
IL145226A (en) 2007-07-04
DE60039043D1 (de) 2008-07-10
CA2366050A1 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
ATE396734T1 (de) Mittel für intravitreale verabreichung zur behandlung oder vorbeugung von augenerkrankungen
Baba et al. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.
De Clercq Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development
BR0316234A (pt) Hidroxiindóis, seu uso como inibidores de fosfodiesterase 4 e processos para a preparação dos mesmos
BR9914097A (pt) Composto, uso do mesmo, composição farmacêutica e método de profilaxia ou tratamento de uma infecção viral e processo para preparação do composto
Hartmann et al. Enhanced in vitro inhibition of HIV-1 replication by 3′-fluoro-3′-deoxythymidine compared to several other nucleoside analogs
HRP20050417B1 (hr) Antiviralni derivati nukleozida
NO20010743L (no) Antivirale indoloksoacetyl-piperazin-derivater
ATE505474T1 (de) Inhibitoren von nukleosidphosphorylasen und nukleosidasen
HUP0303082A2 (hu) Szubsztituált indolil-oxo-acetil-piperazinszármazékok, ezeket tartalmazó készítmények és vírusellenes alkalmazásuk
CA2445744A1 (en) Antiviral nucleoside derivatives
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
HUP9801336A2 (hu) 6-Szubsztituált-pirazolo[3,4-d]-pirimidin-4-on-származékok és az ezeket tartalmazó gyógyszerkészítmények
Cronstein The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism
Fernandez-Larsson et al. Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase.
BR9915480A (pt) Azalìdeos de 13 membros e a sua utilização como agentes antibióticos
US5686428A (en) Pharmaceutical composition
DE50212933D1 (de) Die verwendung von pyrimidinnukleosiden und/oder prodrugs davon zur bekämpfung von nebenwirkungen der &#34;haart&#34; (highly active anti-retroviral therapy) und anderen antiviralen therapien
BR0308403A (pt) Método para tratamento de um distúrbio do olho de um paciente humano ou veterinário, e, uso de um composto
MY105855A (en) Therapeutic nucleotides.
EP0286825A3 (de) Verwendung von 3&#39;-fluro-3&#39;-deoxythymidine zur Herstellung von medicamenten zur Behandlung von Viruskrankheiten
HU223548B1 (hu) Legalább két különböző HIV-1 reverz transzkriptáz inhibitort tartalmazó készítmény HIV-1 fertőzés megelőzésére és kezelésére
BRPI0409683A (pt) 5-hidroxiindóis com grupos n-óxido e seu emprego como agentes terapêuticos
CA1200763A (en) Medicinal composition for the treatment of certain neuroviroses
DE60011637D1 (de) Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties